Article
Oncology
Uros Markovic, Alessandra Romano, Vittorio Del Fabro, Claudia Bellofiore, Anna Bulla, Marina Silvia Parisi, Salvatore Leotta, Massimo Gentile, Clotilde Cangialosi, Iolanda Vincelli, Giuseppe Mineo, Marco Rossi, Massimo Poidomani, Giuseppina Uccello, Cinzia Maugeri, Donato Mannina, Vanessa Innao, Francesco Di Raimondo, Concetta Conticello
Summary: The study shows that daratumumab as a single agent is a safe and well-tolerated regimen in real-life, associated with prolonged progression free survival and overall survival in responding patients. No new safety signals were identified.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Ja Min Byun, Chang-Ki Min, Kihyun Kim, Soo-Mee Bang, Je-Jung Lee, Jin Seok Kim, Sung-Soo Yoon, Youngil Koh
Summary: Extramedullary multiple myeloma (EMD) is a subentity of multiple myeloma (MM) with poor prognosis. This study evaluated the efficacy and safety of daratumumab in combination with multiple drugs for the treatment of EMD. The results showed that the complete remission rate was 35.5% and overall response rate was 67.7%. Long-term responders had a significantly improved progression-free survival. The most common adverse events were hematologic and non-hematologic toxicities.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Massimo Offidani, Laura Corvatta, Sonia More, Davide Nappi, Giovanni Martinelli, Attilio Olivieri, Claudio Cerchione
Summary: Immunotherapy with daratumumab has been approved for the treatment of multiple myeloma and has shown significant efficacy in both relapsed-refractory and newly diagnosed patients, utilizing various mechanisms of action to target CD38. Ongoing trials are exploring new combinations with daratumumab to provide further insights into its potential benefits for MM patients.
FRONTIERS IN ONCOLOGY
(2021)
Letter
Medicine, General & Internal
Elif Hindie
Summary: The study found that treatment with teclistamab resulted in a high overall response rate of 63.0% and a median progression-free survival of 11.3 months in patients with relapsed or refractory myeloma. Additionally, the change in serum levels of soluble BCMA correlated with treatment response.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Philippe Moreau, Alfred L. Garfall, Niels W. C. J. van de Donk, Hareth Nahi, Jesus F. San-Miguel, Albert Oriol, Ajay K. Nooka, Thomas Martin, Laura Rosinol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, Maria-Victoria Mateos, Nizar Bahlis, Rakesh Popat, Britta Besemer, Joaquin Martinez-Lopez, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun X. W. Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani
Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Sagar Lonial, Ajay K. Nooka, Praneetha Thulasi, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Heather A. Potter, Douglas Sborov, Brian E. Zaugg, Rakesh Popat, Simona Degli Esposti, Julie Byrne, Joanna Opalinska, January Baron, Trisha Piontek, Ira Gupta, Reza Dana, Asim V. Farooq, Kathryn Colby, Andrzej Jakubowiak
Summary: Belantamab mafodotin (belamaf) has shown deep and durable responses in heavily pretreated RRMM patients, but can cause corneal events. Guidelines are needed for prompt identification and appropriate management of these events, requiring close collaboration between hematologist/oncologists and eye care professionals.
BLOOD CANCER JOURNAL
(2021)
Article
Medicine, General & Internal
Nikhil C. Munshi, Larry D. Anderson, Nina Shah, Deepu Madduri, Jesus Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David Siegel, Albert Oriol, Philippe Moreau, Ibrahim Yakoub-Agha, Michel Delforge, Michele Cavo, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Alessandro Rambaldi, Donna Reece, Fabio Petrocca, Monica Massaro, Jamie N. Connarn, Shari Kaiser, Payal Patel, Liping Huang, Timothy B. Campbell, Kristen Hege, Jesus San-Miguel
Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Kristine A. Frerichs, Christie P. M. Verkleij, Meletios A. Dimopoulos, Jhon A. Marin Soto, Sonja Zweegman, Mary H. Young, Kathryn J. Newhall, Tuna Mutis, Niels W. C. J. van de Donk
Summary: Daratumumab, a CD38-targeting antibody, shows significant activity in multiple myeloma but resistance often develops. The addition of the PD-L1 checkpoint inhibitor durvalumab at the time of daratumumab failure did not reverse daratumumab-resistance. This suggests that PD-L1 co-targeting may not be sufficient to overcome daratumumab-resistance.
Review
Hematology
Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai Chari
Summary: Daratumumab is a human immunoglobulin G1 kappa monoclonal antibody that targets CD38 and has been approved for use in both newly diagnosed and relapsed refractory multiple myeloma. The subcutaneous formulation of daratumumab has shorter administration time, lower rates of infusion-related reactions, and smaller infusion volume compared to the intravenous formulation. Despite these differences, the pharmacokinetics, safety profile, and efficacy are comparable between the two formulations.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2021)
Article
Medicine, General & Internal
P. G. Richardson, S. Trudel, R. Popat, M- Mateos, A. J. Vangsted, K. Ramasamy, J. Martinez-Lopez, H. Quach, R. Z. Orlowski, M. Arnao, S. Lonial, C. Karanes, C. Pawlyn, K. Kim, A. Oriol, J. G. Berdeja, P. Rodriguez Otero, I Casas-Aviles, A. Spirli, J. Poon, S. Li, J. Gong, L. Wong, M. Lamba, D. W. Pierce, M. Amatangelo, T. Peluso, P. Maciag, J. Katz, Michael Pourdehnad, Nizar J. Bahlis
Summary: In this study, patients with relapsed and refractory multiple myeloma received oral mezigdomide in combination with dexamethasone. The combination therapy showed promising efficacy in heavily pretreated patients with multiple myeloma, with treatment-related adverse events consisting mainly of myelotoxic effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Hematology
Martin Stork, Ivan Spicka, Jakub Radocha, Jiri Minarik, Tomas Jelinek, Alexandra Jungova, Petr Pavlicek, Lenka Pospisilova, Frantisek Sedlak, Jan Straub, Tomas Pika, Zdenka Knechtova, Anna Fidrichova, Ivanna Boichuk, Sabina Sevcikova, Vladimir Maisnar, Roman Hajek, Ludek Pour
Summary: We conducted a real-world evidence (RWE) analysis comparing the treatment of daratumumab, lenalidomide, and dexamethasone (Dara-Rd) to lenalidomide and dexamethasone (Rd) in relapsed/refractory multiple myeloma patients (RRMM). Our analysis included 240 RRMM patients treated with Dara-Rd and 531 RRMM patients treated with Rd as a reference. The results showed that Dara-Rd achieved a significantly higher partial response or better response rate (91.2% vs. 69.9%) and longer median progression-free survival (26.9 months vs. 12.8 months) compared to Rd. In heavily pretreated RRMM patients, the efficacy of Dara-Rd treatment was limited, with the best outcomes observed in minimally pretreated patients.
ANNALS OF HEMATOLOGY
(2023)
Article
Oncology
Lakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, Reid D. Landes, Mathew Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel A. Mitma, Clyde Bailey, Kerri M. Hill, Sharmilan Thanendrarajan, Monica Graziutti, Meera Mohan, Maurizio Zangari, Frits van Rhee, Guido Tricot, Carolina Schinke
Summary: Multiple Myeloma (MM) is a common cancer of the bone marrow that remains incurable despite advancements in therapy. While Daratumumab has improved survival rates, heavily pretreated patients who progress on this treatment have poor clinical outcomes. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be a viable treatment option for selected patients who are refractory to Daratumumab.
Review
Oncology
Laura Gengenbach, Giulia Graziani, Heike Reinhardt, Amelie Roesner, Magdalena Braun, Mandy-Deborah Moeller, Christine Greil, Ralph Waesch, Monika Engelhardt
Summary: Treatment of relapsed/refractory multiple myeloma (RRMM) is a complex process due to the availability of novel therapeutic options and the consideration of patient-, disease- and treatment-related factors. Geriatric assessments and frailty scores are important in providing a more accurate picture of individual patient constitution. Optimal treatment decisions should be based on a comprehensive evaluation of patient health status, disease progression, treatment history, and shared decision making.
Review
Immunology
Elham Roshandel, Haniyeh Ghaffari-Nazari, Mozhdeh Mohammadian, Maryam Salimi, Saeid Abroun, Reza Mirfakhraie, Abbas Hajifathali
Summary: Recent advances in adoptive cell therapy have transformed cancer immunotherapy, with a focus on treating relapsed/refractory multiple myeloma (RR/MM) using natural killer (NK) cells. NK cells exhibit effective cytotoxic activity against myeloma cells and can be derived from the patient or allogenic donors for therapy. Novel cell-based products, such as NK cell lines and CAR-NK cells, offer promising options for off-the-shelf NK cell therapy in MM.
CLINICAL IMMUNOLOGY
(2023)
Article
Oncology
Aimaz Afrough, Shebli Atrash, Barry Paul, Evguenia Ouchveridze, Nausheen Ahmed, Zahra Mahmoudjafari, Anam Bashir, Omar Alkharabsheh, Hamza Hashmi, Al-Ola Abdallah
Summary: This study compared the safety and efficacy of different medication combinations for relapsed or refractory multiple myeloma. The analysis showed that one combination (DPd) had a better response to treatment, but both combinations had similar progression-free survival and overall survival rates. The study highlights the importance of considering patient and disease characteristics when selecting salvage treatments.